These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26793998)

  • 21. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
    Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
    Borchers L; Roider J; Klettner A
    Ophthalmic Res; 2021; 64(3):369-388. PubMed ID: 33011724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
    Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
    Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Bevacizumab on Bcl-2 Expression and Apoptosis in Retinal Pigment Epithelial Cells under Oxidative Stress.
    Kim S; Kim YJ; Kim NR; Chin HS
    Korean J Ophthalmol; 2015 Dec; 29(6):424-32. PubMed ID: 26635460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of aflibercept on the viability and metabolism of ocular cells in vitro.
    Ammar DA; Mandava N; Kahook MY
    Retina; 2013 May; 33(5):1056-61. PubMed ID: 23266881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt.
    Byeon SH; Lee SC; Choi SH; Lee HK; Lee JH; Chu YK; Kwon OW
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1190-7. PubMed ID: 19834034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranibizumab interacts with the VEGF-A/VEGFR-2 signaling pathway in human RPE cells at different levels.
    Ranjbar M; Brinkmann MP; Tura A; Rudolf M; Miura Y; Grisanti S
    Cytokine; 2016 Jul; 83():210-216. PubMed ID: 27163716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
    Peng S; Adelman RA; Rizzolo LJ
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
    Klettner AK; Kruse ML; Meyer T; Wesch D; Kabelitz D; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells.
    Kang S; Choi H; Rho CR
    J Ocul Pharmacol Ther; 2016 Dec; 32(10):671-676. PubMed ID: 27827554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells.
    Brar VS; Sharma RK; Murthy RK; Chalam KV
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):507-11. PubMed ID: 20028259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of commonly used intravitreal anti-vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body.
    Acar U; Erginturk Acar D; Alpaslan Pinarli F; Demir MN; Beyazyildiz E; Ozdemir O; Gulmez Sevim D; Tiryaki M; Sobaci G
    Clin Exp Ophthalmol; 2016 Sep; 44(7):587-596. PubMed ID: 26856706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
    Deissler HL; Deissler H; Lang GK; Lang GE
    Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL; Deissler H; Lang GE
    Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth-related effects of oxidant-induced stress on cultured RPE and choroidal endothelial cells.
    Eichler W; Reiche A; Yafai Y; Lange J; Wiedemann P
    Exp Eye Res; 2008 Oct; 87(4):342-8. PubMed ID: 18640112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The matricellular protein CCN5 prevents anti-VEGF drug-induced epithelial-mesenchymal transition of retinal pigment epithelium.
    Im S; Song MH; Elangovan M; Woo KM; Park WJ
    Sci Rep; 2024 Jun; 14(1):13920. PubMed ID: 38886213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment.
    Golan S; Entin-Meer M; Semo Y; Maysel-Auslender S; Mezad-Koursh D; Keren G; Loewenstein A; Barak A
    BMC Res Notes; 2014 Sep; 7():617. PubMed ID: 25201034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
    Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
    Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):885-94. PubMed ID: 25663437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.